MondayMar 18, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the…

Continue Reading

FridayMar 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology.…

Continue Reading

TuesdayFeb 27, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6 Million Registered Direct Offering

Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under…

Continue Reading

TuesdayFeb 20, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a…

Continue Reading

ThursdayFeb 15, 2024 9:45 am

New England Cannabis Convention To Be Held In Boston, MA

Businesses, leaders, enthusiasts, and service providers of the cannabis spectrum are all invited to the NECANN Boston Convention, the 2nd largest B2B cannabis industry event across the globe. Since its 70th booth convention back in 2015, NECANN has come a long way. This year’s convention will feature over 350 exhibitors, several workshops, five full programming tracks, and a day-long financial/investor summit. The age limit to attend the conference is 18+ unless accompanied by a guardian. The NECANN event is a phenomenal business platform attracting the New England cannabis trading community and other visitors. Influential cannabis industry leaders will be at…

Continue Reading

WednesdayFeb 14, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”)…

Continue Reading

MondayFeb 12, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Shares 2023 Company Update and 2024 Roadmap in Annual Letter

Lexaria, a global innovator in drug delivery platforms, just announced ambitious plans for the 2024 calendar year The letter confirms that the 2024 plans have been made possible by significant strides that were made by the company in 2023 Lexaria looks to build on the momentum gained from the previous year, ultimately asserting market dominance and making 2024 its best year yet Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its ambitious plans for the 2024 calendar year. In his annual letter, Chris Bunka, Lexaria’s CEO, noted that this would mark the year that will…

Continue Reading

ThursdayFeb 01, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2024 GLP-1 Human and Animal Studies Roadmap

Lexaria, a global innovator in drug delivery platforms, has laid down its GLP-1 human and animal studies roadmap for the 2024 calendar year This builds on the success of its human pilot study, which marked a successful undertaking for exploring its patented DehydraTECH(TM) technology for the improved delivery of the GLP-1 drug semaglutide, available commercially in the branded product Rybelsus(R) The company’s chronic dosing animal study and its second human pilot study will commence in Spring and run for 12 weeks. The third human pilot study will start in May or June These studies will evaluate DehydraTECH for the improved…

Continue Reading

MondayJan 29, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) To Hit High Ground in Q2 and Q3 2024 with Animal and Human GLP-1 Study Programs

Lexaria, a global innovator in drug delivery platforms, has announced its GLP-1 research plans for the 2024 calendar year The company will kick off its chronic dosing animal study in March/April, followed by the human pilot study #2, kicking off at around the same time The third human pilot study will start in May/June followed by a chronic dosing human study that will involve 70-90 pre-diabetic and type-2 diabetic human patients These studies will evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies Lexaria Bioscience (NASDAQ: LEXX), a global innovator…

Continue Reading

WednesdayJan 17, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Expedite Human and Animal Studies on DehydraTECH’s Effectiveness on GLP-1 Drugs Following Positive Results from Pilot Study

Lexaria, a global specialist in drug delivery platforms, just announced the final results from its recently completed human Pilot Study #1 on the effectiveness of its patented DehydraTECH(TM) technology on the oral delivery of GLP-1 drug, semaglutide The results showed improved delivery of semaglutide to the bloodstream, with the drug showing approximately 44% higher levels than the control 24 hours after ingestion of a single dose DehydraTECH GLP-1 processed semaglutide also proved to be better tolerated than the control, with the latter resulting in some cases of moderate nausea and diarrhea This milestone brings Lexaria closer to tapping into the…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977